Albemarle CorpALB

Albemarle Corp reported $1.43 billion in revenue for the quarter ended 31 March 2026, alongside net income of $319.1 million and diluted earnings per share of $2.34, according to the latest 10-Q. Operating income clocked in at $233.5 million, while operating cash flow totalled $346.2 million, giving the company genuine cash-generative firepower even as lithium prices wobble. The balance sheet remains sturdy: $15.14 billion of assets, $9.85 billion of shareholders’ equity, and $1.09 billion of cash and equivalents. Capital discipline is evident: quarterly capex was $98.7 million and R&D was a modest $9.2 million, numbers that sit well below the marketing budget on Albemarle’s ‘innovation’ microsite.

What Albemarle actually does is make specialty chemicals that show up in medicines, disinfectants, crop additives and water-treatment systems-all useful, all hard to brand into a headline. The ‘featured products’ page spotlights PorciBrom, an antimicrobial used in pork processing, alongside lithium compounds for energetic materials such as rocket propellants. The site’s cheerful imagery of chemists in lab coats is more aspirational than indicative of volume growth in any single segment. Revenue and profit still depend heavily on lithium and bromine markets, even if the company prefers to talk about health, safety and sustainability.

Filings show inventory net at $1.35 billion, down $212.4 million from the prior annual cycle, suggesting either lean supply chains or softer demand depending on which end of the telescope you prefer. Weighted average diluted shares outstanding were 118.6 million, so EPS of $2.34 is not the result of a shrinking share count. The board’s latest 8-K, filed 23 July 2026, is a procedural affair covering routine officer changes and corporate address updates; there is no fresh guidance, dividend update or segment-level cash flow disclosure. Insider Forms 3 and 4 filed on 23 July and 6 July 2026 show routine holdings and small transactions, but nothing that materially shifts the ownership narrative.

If you want a chart, the TradingView route is https://www.tradingview.com/chart/?symbol=NYSE:ALB. The chart will show price action, but Albemarle’s real story is in the chemistry lab and the contract negotiations for spodumene supply-not the candlesticks. The company’s operating cash flow and net income confirm it is a cash-generative industrial, not a momentum stock; the spread between the glossy sustainability slide deck and the filed numbers is where the tension sits.

The latest SEC submissions JSON for CIK 0000915913 confirms that the only non-routine item in the filing pipeline is the 8-K dated 23 July 2026, while the companyfacts JSON repeats the 10-Q data already captured above. There is no surprise disclosure, no product launch, no regulatory approval and no earnings pre-announcement in the evidence rail. Albemarle’s own product and news search returns only marketing pages and generic innovation copy, which proves little beyond the company’s own PR priorities.

Until the next 10-Q or an investor day that actually breaks down cash flow by segment or ties R&D to a revenue-bearing programme, the file’s strongest read is that Albemarle is a well-capitalised industrial with defensible niches in bromine and lithium, currently enjoying benign lithium pricing and disciplined capital deployment. The rest is narrative.